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Lack of the fragile X mental retardation protein leads to Fragile X syndrome (FXS) while increased levels of FMR1
mRNA, as those observed in premutation carriers can lead to Fragile X- associated tremor ataxia syndrome (FXTAS).
Until recently, FXTAS had been observed only in carriers of an FMR1 premutation (55–200 CGG repeats); however
the disorder has now been described in individuals carriers of an intermediate allele (45–54 CGG repeats) as well as
in a subject with a full mutation with mosaicism.
Here, we report on molecular and clinical data of a male FMR1 mosaic individual with full and premutation alleles.
Molecular analysis of FMR1 and FMRP expression in this subject is consistent with a FXS phenotype. We observed
reduced expression of FMRP in both peripheral blood and brain leading to the FXS diagnosis. In addition, a
dramatic 90% depletion of both FMR1 mRNA and FMRP levels was observed in the blood, as normally observed in
FXS cases, and an even greater depletion in the brain. A clinical report of this patient, at age 71, described
neurodegenerative signs of parkinsonism that were likely, in retrospect, part of a FXTAS scenario as post-mortem
examination shows the presence of intranuclear inclusions, the hallmark pathology of FXTAS.
The findings presented in this study indicate co-morbidity for both FXS and FXTAS in this individual carrying both
full and premutation FMR1 alleles. In addition, based on symptoms and pathological and molecular evidence, this
report suggests the need to redefine the diagnostic criteria of FXTAS.
Keywords: Intranuclear inclusions, FXS, FXTAS, PremutationIntroduction
Two very different disorders arise from a CGG repeat
expansion mutation at the promoter region of the
X-linked FMR1 gene: Fragile X syndrome (FXS) and
Fragile X -associated tremor ataxia syndrome (FXTAS).
Full mutation (FM) individuals with greater than 200
CGG repeats invariably develop FXS, a neurodevelopmental
disorder that is present from birth and produces cognitive
impairment, behavioral, emotional and sleeping problems
[1-3]. Additionally, approximately 60% of children with FXS
can develop autism spectrum disorders (ASD) [4,5]. This
expansion mutation usually causes total methylation of the
FMR1 gene, which consequently becomes silenced, leading
to the absence of the FMR1 protein (FMRP), the underlying
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reproduction in any medium, provided the orIndividuals with shorter ‘premutation’ (PM) expansions
in the FMR1 gene, ranging from 55–200 CGG repeats,
usually do not have developmental disabilities but are at
high risk for developing FXTAS in late adulthood [6].
FXTAS is a late-onset neurological syndrome affecting
older males and females over 50 years of age and presenting
features such as action tremor and ataxia, cognitive decline,
neuropathy, autonomic dysfunction and parkinsonism [7].
The neuropathological signs of FXTAS include white
matter disease and Purkinje cell loss in the cerebellum.
Further, the presence of eosinophilic intranuclear inclusions
throughout the brain [8,9], in testis [10] and in other organs
has been reported in both humans [11] and in the CGG KI
mouse model of PM [12].
PM alleles are associated with increased transcription of
the FMR1 gene and toxic accumulation of CGG-repeat
expanded mRNA that is thought to contribute to the
formation of intranuclear inclusions and to the pathogen-
esis of PM-associated disorders, particularly FXTAS.
The exact mechanism of mRNA-mediated neurotoxicity
remains incompletely understood. One possibility is thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inclusions, which also contain FMR1 mRNA [13]. More
than 30 such sequestered proteins have been identified
within the intranuclear inclusions [14-16]. Included are
Sam68 and the DROSHA/DGCR8 complex which play a
key role in the biogenesis of miRNA and which expression
pattern has been found altered in individuals with FXTAS
[16,17]. However, the sequestration hypothesis may not
fully account for the pathogenesis of FXTAS. PM carriers
can also exhibit reduced FMRP levels, particularly in the
upper PM range [18-21], which can lead to FXS features.
Since the first FXTAS cases were described [22] it was
thought that the syndrome was exclusively limited to PM
carriers. However, very recent studies reported FXTAS in
carriers of intermediate alleles (45–54 CGG repeats)
[23,24] and in a male with methylation mosaicism [25].
Thus, since FXTAS has been linked to toxicity led by
elevated FMR1 mRNA an association, although less
striking, between transcriptionally active FMR1 expanded
alleles across the whole CGG repeat range and FXTAS
could be made. Indeed, cases of individuals who meet
diagnostic criteria of FXTAS but not falling within the
“PM category” have been reported. These constitute a
group of individuals in whom neurological manifestations
seen in the PM related FXTAS spectrum exist. Another
question concerns the presence of intranuclear inclusions
in carriers of alleles outside the premutation range. In fact,
rare and small intranuclear inclusions were observed
in three males with FXS [26]. Intranuclear inclusions
typically occur in FXTAS and are considered one of
the major diagnostic criteria of FXTAS [27], but the
presence of intranuclear inclusions in carriers of alleles
outside the premutation range including intermediate and
FM alleles demonstrates the need to redefine the diagnostic
criteria of FXTAS so that these alleles are included.
Here we report molecular, neuropathological and clinical
characterization of a man with FMR1 size mosaicism.
FMR1 size mosaicism indicates that a person carries both
FM and PM alleles. The subject developed FXS and showed
signs of neurodegeneration during aging. A previous
clinical study on this case reported that the patient
developed parkinsonism that was not thought to be
attributable to FXTAS [23], although parkinsonism is
often co-morbid with FXTAS. This patient also experienced
progressive cognitive decline, which is common in FXTAS.
Molecular post-mortem examination determined the
presence of PM and FM alleles in both peripheral
blood and brain, although in different proportions of
cells. Importantly, we observed intranuclear inclusions, the
hallmark of neuropathology in FXTAS, in the cerebellum,
frontal cortex and hippocampus of this individual.
Our molecular and neuropathological observations
and re-assessment of clinical reports suggest that this
individual was affected with both FXS and FXTAS.Methods
Molecular measures
Consent
Written informed consent for publication of his case report
and any accompanying images was obtained from the
patient earlier in life or from a family member. Tissue
harvest and brain autopsy was performed in accordance
with University of California, Davis, Institutional Review
Board-approved protocols.CGG repeat sizing
CGG repeat size was measured on genomic DNA extracted
from peripheral blood and from brain regions using
standard procedures (Qiagen, Hilden, Germany) and
determined by Southern Blot and PCR analysis as
previously described [28,29].FMR1 mRNA expression levels
Total RNA from all brain regions was isolated using
trizol (Life Technologies, Carlsbad, CA). cDNA synthesis
and QRT-PCR used to quantify FMR1 mRNA levels were
as in [30].FMRP expression
Western blot analysis Postmortem cerebellum, frontal
pole, orbital frontal cortex, medial frontal cortex and
dorsolateral pre-frontal cortex tissues from this case and
from the cerebellum of 8 age matched controls (CGG
ranging from 21 to 48 repeats) were pulverized in liquid
nitrogen and resuspended in 1X RIPA buffer (Cell
Signaling, Beverly, MS) that contained protease and
phosphatase inhibitors. The lysates were sonicated and
spun in a Sorval centrifuge at 18,000 rpm, 4°C. The
supernatants were collected and protein concentrations
measured using a BCA protein assay (Thermo Scientific,
Pierce Biotechnology, Rockford, IL). Approximately
65 μg of protein were loaded in a 10% Criterion SDS/PAGE
gel and ran in 1X MOPS at 25 mAmps for 30 minutes
followed by 80 volts for 4 hours, and proteins were
transferred into a PVDF membrane overnight at 4°C
in 1X Tris/Glycine/SDS with 20% methanol. The
membrane was blocked in LICOR blocking buffer
and hybridized overnight at 4°C with 1:1,300 mouse
anti-FMRP (Chemicon, Temecula, CA) and the next
day for 2 hours at RT with 1:10,000 anti-mouse
secondary antibody (LICOR wv 680 mm). Following
detection the blot was re-hybridized with 1: 200,000
mouse anti-GAPDH (Chemicon, Temecula, CA) anti-
body and the same secondary antibody. Bands were
detected at 169 μm resolution using the Odyssey
infrared scanner.
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Tissue was fixed in paraformaldehyde for at least 48 hours
and paraffin embedded. Four μm paraffin-embedded
sections of cerebellum and frontal cortex mounted on
Thermo Scientific Permafrost Adhesion microscope slides
were deparaffinized and hydrated in a series of fifteen
minute incubations as follows: Safeclear Xylene substitute
(Thermo Fisher Scientific, USA), (v/v) 100% ethyl alcohol
(EtOH), 96% EtOH, 70% EtOH and 50% EtOH followed by
a five minute incubation in Milli-Q H2O. Slides were
washed in 0.1 M Phosphate Buffered Saline (PBS).
Heat-mediated antigen retrieval was performed by
submerging the slides in Citrate buffer (pH 6;
containing 10 mM Citric acid (Sigma) and (v/v) 0.05%
Tween-20 (Acros) followed by boiling for 15 minutes in a
microwave. Slides were allowed to cool to room
temperature (RT) and rinsed in 0.1 M PBS. Endogenous
peroxidase activity was quenched by incubating slides in
0.3% H2O2 for twenty minutes at RT. Slides were rinsed in
0.1 M PBS and incubated for two hours at RT in blocking
buffer containing (v/v) 10% fetal donkey serum (Millipore),
0.1% Triton X-100 (Acros), and (w/v) 0.2% gelatin (Acros).
Slides were incubated in primary antibody incubation
buffer containing mouse anti-FMRP clone 1C3 1:200
(Millipore), (v/v) 2% fetal donkey serum, 0.2% Triton
X-100, and (w/v) 0.2% gelatin overnight at RT. Sections
were rinsed in 0.1 M PBS and incubated in secondary
antibody buffer containing biotin-conjugated donkey anti-
mouse secondary antibodies 1:200 (Jackson), (v/v) 2% fetal
donkey serum, 0.2% Triton X-100, and (w/v) 0.2% gelatin
at RT for one hour. Sections were rinsed in 0.1 M PBS
and the immunoenzymatic reaction was visualized with an
ABC horseradish peroxidase kit using the chromagen
DAB (Vector). Sections were washed in 0.1 M PBS and
Milli-Q H2O. Slides were dehydrated in a series of fifteen
minute incubations as follows: (v/v) 50% EtOH, 70%
EtOH, 96% EtOH, 100% Chloroform, 96% EtOH, 100%
EtOH and Safeclear (Fisher) and coverslipped in DPX
mounting medium (EMS).
Quantification of intranuclear inclusions
Neuropathologic features from single H & E stained 4 μm
paraffin sections were quantified from the frontal cortex,
hippocampus, temporal cortex, and cerebellum. A priori
selection criteria were applied to select anatomically
constrained regions of interest and every cell within that
region was counted at 1000X total magnification using a




The patient was a high-functioning man with FXS who was
initially diagnosed at age 60 because of behavioraloutbursts, which required medical treatment. He was found
to be a mosaic for the FMR1 gene and his IQ at age 60 on
the WAIS-R showed a verbal IQ of 69, a performance
IQ of 67 and a full scale IQ of 67. His clinical exam-
ination demonstrated typical features of FXS including
a mildly long face, large and mildly prominent ears,
macroorchidism, in addition to perseverative speech,
verbal outbursts, paranoid ideation and anxiety that
interfered with sleep. He was placed on buspirone
and aripiprazole for his behavioral outbursts. At age 71 he
developed a history of balance difficulties with falling and
slowness in his motor movements. He also described
memory problems and his Mini-Mental Status Examination
(MMSE) was 25/30. He had masked facies, hypotonic
speech and increased tone in the upper extremities without
rigidity or tremor. He demonstrated a stooped posture and
shuffling gait. Because of his parkinsonian features the
aripiprazole was discontinued. His MRI demonstrated
subcortical white matter disease and dilated ventricles but
he did not have the middle cerebellar peduncle (MCP) sign.
Over the next few years he gradually developed more
bradykinesia, rigidity and difficulties with walking. He also
had depression, which had been an intermittent problem
for him since age 60. He was treated with counseling and
fluoxetine in addition to his buspirone. At age 77 he
had significant cognitive deficits and his MMSE
dropped to 13/30. Just before his death he developed
an intermittent tremor and he had only limited communi-
cation abilities. He was reported in a medical journal [23]
and was thought to have Parkinson disease in addition to
dementia. He died at age 77 and his brain was extracted for
the following neuropathological studies.
The family history was significant in that his brother
had the full mutation and fragile X syndrome and was
lower functioning cognitively than him. His mother, who
was a carrier, died at age 75 and developed lung cancer
but had a long history of depression and also had
dementia before death.
Gross and microscopic findings
External examination of the cerebral hemisphere showed
moderate cortical atrophy and mild atrophy of the superior
and middle lobules of the cerebellar vermis. The lateral
ventricle was moderately dilated as seen on serial coronal
sections. Numerous representative sections from all regions
of the brain were taken. H&E stains were performed on
cerebellum, frontal cortex and hippocampus. A severe
vascular hyalinopathy was present throughout the brain,
and in the cerebrum involving even subcortical vessels.
Congophilic angiopathy was not seen.
FMR1 molecular measures
FMR1 mosaicism was identified by Southern Blot and
PCR analysis in both peripheral blood and brain tissues.
Figure 1 Southern blot analysis of genomic DNA isolate from two
controls: C1 (negative control, normal female with two normal
alleles and the corresponding 5.2 Kb and 2.8 Kb bands (methylated
and unmethylated alleles respectively) and C2 (positive control, full
mutation male with a methylated band of ~ 800 CGG repeats). Both
a premutation allele and a full mutation alleles are present in blood
(lane 1), cerebellum (lane 2), and frontal cortex (lane 3) of the
proband. DNA marker (M) 1 kb ladder is shown in Lane 1.
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FM alleles (CGG = 300, 440, and 530) and a PM allele
in ~25% of cells (78 CGG repeats) in peripheral
blood. Genotyping analysis of DNA isolated from
post-mortem brain tissues showed that similar FMR1
mutation patterns (CGG = 300, 390, 530 and 78 in
cerebellum, and CGG = 320, 400, 600 and 78 in
frontal cortex) were conserved in the brain (Figure 1).
However, the proportion of blood cells (percent of
methylation) carrying a full mutation was different in
peripheral blood (~75%) compared to what observed
in both cerebellum (94%) and in frontal cortex (95%)
suggestive of greater depletion of the premutation allele in
the brain.
FMR1 mRNA gene expression analysis showed ~ 0.4
fold expression levels from the normal in peripheral
blood [23]. Although only ~5-6% of cells carried a
premutation allele in brain they were transcriptionally
active; indeed the presence of FMR1 mRNA was detectable
in both, the cerebellum (0.06 ± 0.001) and frontal cortex
(0.05 ± 0.008). Brain sections from the same brain
block that were used for determining CGG repeat size
by Southern Blot and FMR1 mRNA levels by QRT-PCR
were used for determining FMRP expression by Western
Blot (WB) analysis and immunohistochemistry (IHC). WB
analysis did not detect any FMRP (Figure 2). However, we
found that despite the dramatic reduction of FMR1
expression and absence of FMRP signal by WB, IHC
showed detectable levels of FMRP expression (Figure 3).
Qualitative examination and distribution of FMRP
expression in the cerebellum and dorsolateral pre-frontal
cortex compared to a normal age-matched control by
IHC, which amplifies antigen signal allowing detection of
low levels of protein expression, showed numerous cere-
bellar Purkinje and molecular layer cells immunoreactive
for FMRP. FMRP-positive and FMRP-negative cells, in
addition to the overall reduction in immunoreactivity,
were observed compared to a normal age matched
control. FMRP immunoreactive cells with the morphology
of excitatory neurons in the dorsolateral pre-frontal cortex
were also present (Figure 3). Based on both WB and
IHC analyses we qualitatively estimate that the proband
presented an approximately ~95% reduction of FMRP
expression, consistent with his FXS phenotype. Importantly,
similar visualization of sparse, but clearly positive FMRP
staining by IHC in the absence of an FMRP-corresponding
band on WB has been reported in three cases of FXS [26].
Quantitative analysis of intranuclear inclusion number
To examine the contribution of the PM allele to the
patient’s decline during aging we asked whether
intranuclear inclusions were present in this individual
that would suggest the presence of FXTAS pathology.
Throughout this examination we largely focused onthe granule cell population as studies in the CGG KI
mouse model of PM have shown similar numbers of
inclusions in cerebellar, olfactory bulb, and hippo-
campal granule cell populations [31-33]. Intranuclear
inclusions were observed in three different regions
of the brain (Figure 4). See Table 1 for a comparison
Figure 2 WB shows lack of FMRP in cerebellar and frontal
cortex protein extracts. Cerebellar protein extracts from 4 typically
age-matched developing controls show the presence of FMRP (75
KDa). No FMRP expression was detected in extracts from cerebellum
(Cer) and 3 different frontal cortex regions (frontal pole (FP), orbital
frontal cortex (OFC); and dorso lateral pre-frontal cortex (DLPFC).
GAPDH (37 KDa) was used as a loading control.
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previously by [8,26,34].
Examination of a coronal hippocampal section from a
region proximate to the level of the retrosplenial cortex
identified the presence of intranuclear inclusions in low
numbers and with irregular distribution. As can be seen
in Table 1, when every granule cell and astrocyte in the
granule cell layer of the dentate gyrus were counted, the
percentage of cells with intranuclear inclusions was
estimated to be 2.82% in granule cell nuclei (15 inclusions
in 532 cells counted) and 6.35% in astroglial nuclei
(8 of 126 cells counted). The granule cell layer was
chosen as a region of interest to compare our current
estimates with previous accounts which approximated 1%
to 7% of granule cells and >25% astrocytes in the granule
cell layer containing intranuclear inclusions in male and
female cases with FXTAS [8,34]. In addition, hippocampus
sections from 5 age-matched, non-FXS control cases
reported by [26] were counted using identical methods,
and no intranuclear inclusions were observed in any
control case.
Morphological analysis allowed clear definition of the
CA1/subiculum border and the CA3/CA1 border.
Pyramidal neurons and astroglial cells were counted
in the pyramidal cell layer in CA1. The percentage of
cells with intranuclear inclusions was estimated to be
4.09% of pyramidal neurons (5 of 122 cells counted)
and 4.49% of astroglial cells (11 of 245 cells counted).
The CA3 and the Hilus were, however, not well represented
in these sections and were not counted. Every neuron and
astroglial cell was counted in this section similar to
the dentate gyrus granule cells.
Similar to the quantifications in the hippocampus, the
frontal cortex and temporal cortex were sampled. In this
case, a single gyrus was chosen by marking the slide
prior to placing under the microscope. The gyrus and
sulci on either side were completely sampled and all
neurons and astroglia were counted, as well as the
number of intranuclear inclusions in each cell type
(Temporal cortex: 2.12% of neurons (4 of 189 cells)and 8.03% of astroglial cells (25 of 311 cells); Frontal
cortex: 3.40% of neurons (7 of 206 cells) and 4.51%
of astroglial cells (19 of 421 cells). The temporal cortex and
frontal cortex were chosen for comparison with previous
studies of inclusions in male and female subjects with
FXTAS [8,34], as well as a report in FXS [26].
To quantify the presence of intranuclear inclusions in the
cerebellum, a protocol used to quantify neuropathological
features in FXS [35] was modified to quantify inclusions.
Prior to placing the section under the microscope,
the slide was marked to select a single cerebellar
folium. The selection criterion was to select the folium
that showed the fewest histological artifacts (i.e., tissue
shredding, separation of granule cell layer from Purkinje
cell layer, etc.). The internal granule cell layer in a cerebellar
section was sampled and all neurons and astroglial quanti-
fied. The observed number of intranuclear inclusions in this
population was 2.10% of granule cells (30 of 142 counted)
and 6.52% of astroglial cells (42 of 642 counted). The
Purkinje cell population was also sampled, but no
inclusions were identified. The molecular layer was
not rigorously sampled, but inclusions were present in
very low numbers (i.e., <<1%). A summary of intranuclear
inclusion estimates is provided on Table 1.
Discussion
This study examines the case of a male with FMR1 size
mosaicism consisting of a FM and a PM allele who was
diagnosed with FXS and whose phenotype was related to
the striking reduction of FMRP expression in the brain.
Later in life this individual also showed features congruent
with the minor diagnostic criteria for FXTAS, but this
diagnosis was not given due to lack of appreciable FMR1
mRNA levels and the presence of FXS symptomatology
[23]. However, upon post mortem analysis we observed
the presence of intranuclear inclusions throughout the
brain, one of the major diagnostic criteria for FXTAS [27].
FMR1 mRNA expression, most likely due to the presence
of a PM allele in a small percent of cells, was detected in
peripheral blood [23] and in two brain regions in this
study. Although the overall level of FMR1 mRNA
throughout the brain and in different brain regions
(cerebellum and frontal cortex) did not seem elevated,
it was likely to be elevated in cells that were actually
transcriptionally active (cells with a PM allele) and
therefore leading to RNA toxicity due to the presence
of the CGG repeat expanded alleles as reported in
other cases [26]. Thus, the presence of toxic expanded
mRNA is likely responsible for the FXTAS phenotype
observed in this individual.
It has been shown that expansion of the CGG repeat
leads to sequestration of a number of proteins, including
DROSHA and DGCR8, which are key players in the
microRNA biogenesis as described in [16] and indeed a
Figure 3 Immunohistochemistry demonstrates reduced FMRP levels in the cerebellum and frontal cortex of the proband. Paraffin
embedded tissue sections from the proband and controls were immunostained with anti-FMRP (clone 1C3) antibody. (A,B): A comparison of
FMRP immunoreactivity (FMRP-IR) in the cerebellar cortex of SK relative to age-matched control tissue demonstrates reduced FMRP-IR in the
molecular layer (ML), purkinje cell layer (PCL) and granule cell layer (GCL). (C) FMRP immunoreactive purkinje cells present in cerebellar cortex of a
control subject. The granule cell layer is characterized by significant FMRP expression in control sections which is dramatically reduced in the
proband. (D, E) FMRP-positive (black arrowhead) and FMRP-negative Purkinje cells (yellow arrowhead) were present in the cerebellum of SK. (F)
FMRP-positive cells in the molecular layer of cerebellar cortex of a control section. (G) Levels of FMRP are significantly reduced in the molecular
layer of SK. (H) FMRP-positive cells with the morphology of excitatory neurons in the frontal cortex (FC) of SK. Scale bar in A = 200 μm, applies to
A,B. Scale bar in C = 50 μm, applies to C-E. Scale bar in F = 50 μm, applies to F,G. Scale bar in H = 25 μm.
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in neural cells from FXTAS cases [17]. It is interesting
that a small percentage of cells expressing the FMR1
premutation, as little as 5-6% in the cerebellum and
in the frontal cortex, may contribute to a process of
neural degeneration in this individual in addition to his
parkinsonism. As cells in our brain are involved in many
networks, alterations such as protein sequestration andmRNA toxicity in small pockets throughout the brain
could potentially lead to significant pathway dysregulation
(such as microRNA biogenesis and glutamate signaling
pathway) amounting to major signaling network break-
down. In addition, when the subject developed symptoms
of FXTAS, he had already experienced a great deficit of
FMRP and the consequent related phenotype. This may
suggest that early in life the presence of the PM allele,
AB C
_____
Figure 4 Intranuclear Inclusions. (A) A pyramidal neuron and an
astroglial cell in the frontal cortex containing intranuclear inclusion
bodies. Note the pyramidal cell nucleolus adjacent to the
intranuclear inclusion and the heterochromatin of the astroglial cell
gathered up against the edges of the nucleus. (B) Granule neuron in
the dentate gyrus of the hippocampus with an intranuclear
inclusion body. (C) Granule neuron in the cerebellar granule cell
layer with an intranuclear inclusion. Note the heterochromatin is
pushed away from the inclusion, forming a dense gathering at the
nuclear envelope. Scale bar = 50 μm applies to all plates.
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ameliorating some of the FXS phenotype. In fact, the
patient was not diagnosed with FXS until late in life
at age 60.
The present finding of symptoms and pathological and
molecular evidence of FXTAS in a FXS mosaic male,
raises a number of diagnostic issues for FXTAS. The
finding also raises concerns since, during antemortem
investigations this case received a diagnosis of parkinsonismTable 1 Intranuclear inclusion counts
Frontal Cortex Temporal Cortex
(Gray Matter) (Gray Matter) (
Neurons Astroglia Neurons Astroglia N
Case 1 7 of 206 19 of 421 4 of 189 25 of 311 30
mean 3.40% 4.51% 2.12% 8.03%
Greco et al., 2006 [8] 4.4% 16.7% na na
Tassone et al., 2012 [34] 5.6% 4.24% 11.59% 9.85%
Hunsaker et al., 2011 0.4% 0.93% na na
na Data not available.
This table shows the number of neurons and astroglia containing intranuclear inclu
are intranuclear inclusion prevalence data from male FXTAS cases reported by [8], f
context for where along the fragile X associated disorder spectrum this size mosaicwith cognitive decline based on clinical features, rather than
a diagnosis of FXTAS [23]. What this case brings to light is
the need for increased vigilance and rigor in the application
of diagnostic criteria to carriers of expanded CGG repeats
as pertaining to FXTAS, separate from other non-FXTAS
movement disorders although the two problems, FXTAS
and Parkinson Disease, can occur together.
The diagnosis provided by our group was based on the
knowledge of the neurobiology of FXS and FXTAS at
the time. Most working models of FXS pathogenesis
posit that FXS is the result of dramatically reduced or
absent expression of biologically active FMRP (i.e., no
FMRP expression due to the expansion of the CGG
repeats or deletion or mutation in the coding region of
the FMR1 gene). In contrast, FXTAS is believed to result
from a toxic RNA gain of function mechanism resulting
in alterations of cellular function [36]. In this case, and
based on what was heretofore presumed about the
neurobiology of FXS and FXTAS, having >90%
reduction in FMRP levels and only ~40% of normal
mRNA expression levels was sufficient to suggest FXTAS
as a potential diagnosis.
During antemortem investigations, the diagnosis of
parkinsonism was made rather than FXTAS-though
the potential for a patchy presentation of FXTAS-like
symptoms was mentioned as a remote, albeit unlikely
possibility at the time. After receiving these diagnoses
and following the death of this individual, postmortem
brain tissue was available for analysis. Similarly to the
three cases previously reported [26], a sparse distribution
of intranuclear inclusions was present and a patchy
expression of FMRP immunoreactivity was apparent in
brain. As can be seen in Table 1, the number of inclusions
is intermediate to what has been reported before in
FXTAS cases [8,37] and the three FXS cases reported [26].
It is uncertain whether the presence of inclusions always
means that a diagnosis of FXTAS is certain and perhaps it
should serve as markers of cellular processes associated
with the presence of expanded CGG repeat-transcriptsCerebellum Hippocampus–CA1 Hippocampus–DG
Granule Cell Layer) (Pyramidal Cell Layer) (Granule Cell Layer)
eurons Astroglia Neurons Astroglia Neurons Astroglia
of 1424 42 of 644 5 of 122 11 of 245 15 of 532 8 of 126
2.10% 6.52% 4.09% 4.49% 2.82% 6.35%
na na 10.1% 10.3% 2.1% 26.6%
na na 6.59% 8.84% 4.66% 11.56%
na na na na 0.68% 1.34%
sions in this Case as a function of the number of cells counted. Also included
emale FXTAS cases reported by [37], and male FXS reported by [26] to provide
case fits.
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searching for the presence of intranuclear inclusions in post
mortem FXTAS brains is akin to applying NIA-Reagan and
Braak criteria to post mortem tissue obtained from
probable Alzheimer Disease cases; that is that the
diagnosis of FXTAS can be confirmed post mortem
using intranuclear inclusions as a quantitative marker.
In conclusion, it is likely that the neuropathological
changes of FXTAS were present here and that this
patient had FXS and FXTAS, and Parkinson Disease.
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